戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              IHD (29.8%), CKD (24.5%) and stroke (16.0%) are the most
2                                              IHD in patients with T2DM had an especially negative inf
3                                              IHD risk by vegetarian status was estimated by using mul
4                                              IHD risks were estimated with multivariable Cox regressi
5 ncrement; 95% CI) of CVD (0.96; 0.85, 1.09), IHD (0.90; 0.81, 1.04), stroke (1.09; 0.86, 1.39), or HF
6 average follow-up of 11.6 y, there were 1235 IHD cases (1066 hospital admissions and 169 deaths).
7                           We documented 1660 IHD deaths during 804,433 person-years of follow-up.
8               During 12 y of follow-up, 1807 IHD events occurred.
9 correlation [r]=0.62), indicating that the 2 IHD phenotypes had differing risk profiles.
10 ely 7 y of follow-up, 372 CVD deaths and 249 IHD deaths occurred.
11  occurred, including 396 CVD-related and 266 IHD-related deaths.
12 eimer's disease (1.17, 95% CI 0.96 to 1.43), IHD (0.96, 95% CI 0.80 to 1.14), lipids, glycemic traits
13 y (IQR: 9.9-10.8 y), a total of 641 CVD, 465 IHD, 172 stroke, and 265 HF events occurred.
14                      A coal combustion PM2.5 IHD HR = 1.05 (95% CI: 1.02, 1.08) per microgram/cubic m
15                  Overall, 23% had HFpEF (52% IHD), 21% had HFmrEF (61% IHD), and 55% had HFrEF (60% I
16 IHD deaths and 9,931 (95% UI: 8,429; 11,532) IHD events over the first 10 years.
17 had HFmrEF (61% IHD), and 55% had HFrEF (60% IHD).
18 23% had HFpEF (52% IHD), 21% had HFmrEF (61% IHD), and 55% had HFrEF (60% IHD).
19 sed 313,041 individuals and 11,995 CVD, 7534 IHD, and 2686 fatal IHD events.
20 95% uncertainty interval [UI]: 1,765; 2,851) IHD deaths and 9,931 (95% UI: 8,429; 11,532) IHD events
21 prised 501,791 unique individuals and 11,869 IHD, 8244 stroke, and 14,449 diabetes events.
22 on that TSH, FT4 or TPOAb positivity affects IHD, despite potential effects on its risk factors.
23 ectories of work disability before and after IHD and stroke events.
24 , 1.08) per microgram/cubic meter, versus an IHD HR = 1.01 (95% CI: 1.00, 1.02) per microgram/cubic m
25 VD mortality (HRs between 0.68 and 0.75) and IHD mortality (HRs between 0.55 and 0.70).
26 rease; 95% CI] of CVD (0.87; 0.78, 0.97) and IHD (0.86; 0.75, 0.97), as well as nonsignificant invers
27 oordination are critical elements of ACS and IHD control strategies.
28 s well as in access to treatment for ACS and IHD.
29 quately address the global burden of ACS and IHD.
30 ween low-density lipoprotein cholesterol and IHD genetic load is more than multiplicative, supporting
31 and low-density lipoprotein cholesterol, and IHD to create GRSs for each factor.
32 decaffeinated, may lower the risk of CVD and IHD mortality in patients with a prior MI.
33 the risk of cardiovascular disease (CVD) and IHD mortality when the sum of SFAs and trans fatty acids
34 d T2DM, depression, Alzheimer's disease, and IHD and its risk factors by genetically predicted coffee
35 ive protein and between the lipoproteins and IHD.
36 tes, hypertension, sleep apnea, prior MI and IHD (all P<0.001) as well as AF, stroke and HF (all P=0.
37                    HRs for CVD mortality and IHD mortality for theoretical, isocaloric replacement of
38                  Patients with both T2DM and IHD had the highest mortality, which was further accentu
39  in ischemic heart disease (IHD) we assessed IHD risk and risk factors according to genetically predi
40                                  On average, IHD deaths in South Asia, North Africa and the Middle Ea
41                        Policy costs, avoided IHD events and deaths, health-adjusted life years (HALYs
42 rt Failure Registry with respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, and all-c
43 iable adjustment, associations with baseline IHD were similar for HFmrEF and HFrEF and lower in HFpEF
44 ed significant positive associations between IHD and several UF components including EC, Cu, metals,
45 ed significant positive associations between IHD mortality and both fine and ultrafine particle speci
46 attenuated by a 25.3% decrease in per capita IHD burden (decreased rate).
47  CD34(+) percentage in patients with chronic IHD correlated with decrement in LVEF (-2.9% versus +0.7
48 us -0.02%; P=0.021 for patients with chronic IHD).
49                                  Conclusions IHD remains the single largest cause of death in countri
50 to define the risk profile of a contemporary IHD phenotype.
51 and dietary magnesium with incidence of CVD, IHD, and fatal IHD.
52 o-potassium excretion ratio and risk of CVD, IHD, stroke, or HF.
53 rs of follow-up, 3401 participants developed IHD and 1708 developed MI.
54 s of follow-up 13 945 participants developed IHD.
55 ients with CKD had higher risk of developing IHD (16.3%), stroke (8.9%) and all-cause mortality (8.7%
56  a higher risk (9.2% to 24.4%) of developing IHD or CKD, respectively.
57 , a 26% reduction in ischemic heart disease (IHD) (RR: 0.74; 95% CI: 0.63-0.88), a 32% reduction in s
58  = 5,818 deaths) for ischemic heart disease (IHD) after adjustment for dose fractionation.
59 mes of patients with ischemic heart disease (IHD) after ventricular tachycardia (VT) ablation.
60 e (ALT) levels with ischaemic heart disease (IHD) and cardiovascular disease (CVD) risk factors are i
61 e of birth weight in ischemic heart disease (IHD) and lipids.
62 s is associated with ischemic heart disease (IHD) and related clinical events, sex-specific differenc
63  (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortali
64 r long-term risks of ischemic heart disease (IHD) and whether such risks are due to shared familial f
65                      Ischemic heart disease (IHD) burden consists of years of life lost from IHD deat
66           Background Ischemic heart disease (IHD) has been considered the top cause of mortality glob
67 e intake and risk of ischemic heart disease (IHD) has not been fully explored in Asian populations kn
68 agnesium and risk of ischemic heart disease (IHD) have yielded inconsistent results, in part because
69 e pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fractio
70       Recognition of ischemic heart disease (IHD) is often delayed or deferred in women.
71                      Ischemic heart disease (IHD) is one of the leading causes of death worldwide.
72                      Ischemic heart disease (IHD) is the greatest single cause of mortality and loss
73                      Ischemic heart disease (IHD) is the leading cause of death worldwide.
74 ase (CVD) mortality, ischemic heart disease (IHD) mortality, and all-cause mortality in patients with
75 m PM2.5 exposure and ischemic heart disease (IHD) mortality, as established in the American Cancer So
76                      Ischemic heart disease (IHD) occurred in 62% of patients with T2DM and 47% of th
77 lity attributable to ischemic heart disease (IHD) require an understanding of the changing epidemiolo
78 ferences in incident ischemic heart disease (IHD) risk between vegetarians and nonvegetarians.
79 factor confluence on ischemic heart disease (IHD) risk by testing whether genetic risk scores (GRSs)
80 cid (SFA) intake and ischemic heart disease (IHD) risk is debated.
81 y leads to increased ischemic heart disease (IHD) risk, but the risk is thought to be mediated throug
82 ngiography in stable ischemic heart disease (IHD) varies widely.
83             Previous ischemic heart disease (IHD) was a predictor of in-hospital and 30-day cardiac m
84  thyroid function in ischemic heart disease (IHD) we assessed IHD risk and risk factors according to
85 vents (MCEs), 37,992 ischemic heart disease (IHD), and 42,951 strokes were recorded.
86 use, cardiovascular, ischemic heart disease (IHD), and respiratory mortality.
87 diovascular disease, ischemic heart disease (IHD), and stroke) in adult women.
88 pital admissions for ischemic heart disease (IHD), congestive heart failure (CHF), and overall CVD we
89 farction (MI), other ischemic heart disease (IHD), congestive heart failure (CHF), stroke, chronic ki
90 ial infarction (MI), ischemic heart disease (IHD), heart failure (HF), atrial fibrillation (AF), stro
91 ntly associated with ischemic heart disease (IHD), heart failure (HF), atrial fibrillation, and perip
92 o metabolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes
93 VD), including fatal ischemic heart disease (IHD), is unclear.
94 ciation of IDO1 with ischemic heart disease (IHD), ischemic stroke and their risk factors, all-cancer
95 sociate with risk of ischemic heart disease (IHD), myocardial infarction (MI), and death in the gener
96 FH) in subjects with ischemic heart disease (IHD), premature IHD, and severe hypercholesterolemia (lo
97  legumes and risk of ischemic heart disease (IHD), stroke, and diabetes have not been well establishe
98  were CVD [including ischemic heart disease (IHD), stroke, and vascular interventions], IHD, stroke,
99 r's disease, but not ischemic heart disease (IHD).
100 ted patients without ischemic heart disease (IHD).
101 l and in relation to ischemic heart disease (IHD).
102 known risk factor of ischemic heart disease (IHD).
103 VM) in patients with ischemic heart disease (IHD).
104 tion and outcomes of ischemic heart disease (IHD).
105  the pathogenesis of ischemic heart disease (IHD).
106 A) is independent of ischemic heart disease (IHD).
107 with a lower risk of ischemic heart disease (IHD).
108 al infarction [MI], ischaemic heart disease [IHD], cardiomyopathy, and heart failure).
109 Ischemic and/or non-ischemic heart diseases (IHD and/or NIHD) were detected in 147 (86.5%), 13 (7.6%)
110 erative knowledge of intrahepatic bile duct (IHD) anatomy is critical for planning liver resections,
111                                      The EHR IHD phenotype was most strongly correlated with ARIC met
112                                      The EHR IHD risk profile differed from ARIC and indicates that t
113 es between the ARIC risk factors and the EHR IHD were modestly linearly correlated with hazards ratio
114                                  Established IHD was an important prognostic factor across all HF typ
115 Cox proportional hazard models, we estimated IHD mortality hazard ratios (HRs) for PM2.5, trace const
116 als and 11,995 CVD, 7534 IHD, and 2686 fatal IHD events.
117 IHD (RR: 0.83; 95% CI: 0.75, 1.05) and fatal IHD (RR: 0.61; 95% CI: 0.37, 1.00).
118 nesium with incidence of CVD, IHD, and fatal IHD.
119  of nuts was inversely associated with fatal IHD (6 studies; 6749 events; RR per 4 weekly 28.4-g serv
120 000 person-years ranged from 9.5 to 12.2 for IHD, 7.7 to 9.1 for CHF, and 15.8 to 19.2 for overall CV
121  in this age group were 1.18 (1.08-1.29) for IHD and 1.14 (1.01-1.29) for total stroke.
122 io estimate of 1.19 (95% CI: 1.08, 1.31) for IHD in association with a 10-mug/m3 increase in PM2.5 is
123 -2.63) for diabetes, to 1.44 (1.40-1.48) for IHD.
124 1 mmol/L higher TC were 1.44 (1.29-1.61) for IHD and 1.20 (1.15-1.25) for ischemic stroke.
125 .40 (95% confidence interval, 1.20-1.62) for IHD and 1.57 (1.28-1.93) for MI, in individuals with 3 t
126 n rate per 100,000 person-years of 242.7 for IHD (P = 0.02), 271.8 for CHF (P = 0.01), and 497.2 for
127 cases < = 76 014, non-cases < = 264 785) for IHD.
128 the 10 years following delivery, the aHR for IHD associated with pre-term delivery (<37 weeks) was 2.
129 to compute adjusted hazard ratios (aHRs) for IHD associated with pregnancy duration, and cosibling an
130  total cardiovascular death, 6 estimates for IHD, and 7 estimates for death from stroke.
131 iables interacted with statin use except for IHD (P=0.001), with a hazard ratio of 0.76 (95% confiden
132 ry should be recognized as a risk factor for IHD in women across the life course.
133 ery was a strong independent risk factor for IHD.
134                    The hazard ratio (HR) for IHD was 1.19 (95% CI, 1.06-1.33) for a 100-g/d increment
135  fish, dairy products, and eggs and risk for IHD in the pan-European EPIC cohort (European Prospectiv
136                                     Risk for IHD was positively associated with consumption of red an
137                         HRs were similar for IHD mortality.
138                                  Sources for IHD mortality estimates were country-level surveillance,
139  might be a potential therapeutic target for IHD, diabetes and prostate cancer.
140  from 1973 to 2015, who were followed up for IHD through the end of 2015.
141 ation between age at menarche and death from IHD was observed only among nonsmoking populations or po
142 sed radiation-associated risks of death from IHD, in particular, significantly increased radiation ri
143                                  Deaths from IHD and acute coronary syndrome (ACS) occur, on average,
144 ) burden consists of years of life lost from IHD deaths and years of disability lived with 3 nonfatal
145 d data, we analyzed trends of mortality from IHD and 3 noncommunicable diseases (lung cancer, stroke,
146 s the top cause of death, but mortality from IHD has progressively decreased from 2005 to 2015.
147          About 32.4% of the growth in global IHD disability-adjusted life-years between 1990 and 2010
148 emic Heart Disease study, of whom 10 668 had IHD diagnosed between 1977 and 2011.
149 ral and environmental determinants of higher IHD mortality.
150 tes was significantly associated with higher IHD risks (HR per 5% of energy: 1.27-1.37).
151 er SFA intake was not associated with higher IHD risks.
152 apacity of risk factor confluence to improve IHD risk prediction is questionable.
153 days increased to 83.9 (95% CI 80.6-86.5) in IHD; to 179.5 (95% CI 172.4-186.8) in stroke, a six-fold
154 nt inverse dose-fractionation association in IHD mortality requires further investigation.
155 ed life years (HALYs) gained, and changes in IHD-related healthcare costs saved were estimated over 1
156  5 countries showed a progressive decline in IHD mortality, with a decline in smoking and hypertensio
157 2.4-186.8) in stroke, a six-fold increase in IHD and 14-fold in stroke.
158 l traffic, were associated with increases in IHD mortality in this nationwide population.
159 nt decreases close to the pre-event level in IHD but remains particularly high after stroke; among pa
160 ssociations between eating nuts and incident IHD and diabetes and eating legumes and incident IHD.
161 and diabetes and eating legumes and incident IHD.
162 ed with hazards ratio estimates for incident IHD in ARIC (Pearson correlation [r]=0.62), indicating t
163  of nut and legume consumption with incident IHD, stroke, and diabetes.
164                                The increased IHD risk because of obesity was partly mediated through
165                                The increased IHD risk caused by obesity was partly mediated through e
166  (IHD), stroke, and vascular interventions], IHD, stroke, and new-onset heart failure (HF).
167           In the 310 participants with known IHD (18% women, 82% men), most baseline characteristics
168 vary greatly by source, and that the largest IHD health benefits per microgram/cubic meter from PM2.5
169 Total SFA intake was associated with a lower IHD risk (HR per 5% of energy: 0.83; 95% CI: 0.74, 0.93)
170                               Slightly lower IHD risks were observed for higher intakes of the sum of
171                                    The lower IHD risk observed did not depend on the substituting mac
172  a vegetarian diet was associated with lower IHD risk, a finding that is probably mediated by differe
173      Similar patterns were observed for MCE, IHD, and stroke.
174                                         More IHD deaths occurred in South Asia in 2010 than in any ot
175                                          New IHD (n = 13521) and stroke (n = 7162) cases in 2006-2008
176  prevalence of IHD and a greater risk of new IHD events.
177             Those with IHD, particularly new IHD events, were also more likely to change to a lower E
178 6; 95% CI: 0.69, 0.84; I(2) = 28%), nonfatal IHD (4 studies; 2101 events; RR: 0.78; 0.67, 0.92; I(2)
179 nd years of disability lived with 3 nonfatal IHD sequelae: nonfatal acute myocardial infarction, angi
180  had an increased risk of fatal and nonfatal IHD (multivariable HR: 1.60; 95% CI: 1.28, 2.00) compare
181 ecreased age-standardized fatal and nonfatal IHD in most regions since 1990, population growth and ag
182    The number of people living with nonfatal IHD increased more than the number of IHD deaths since 1
183 number of IHD deaths since 1990, but >90% of IHD disability-adjusted life-years in 2010 were attribut
184 cally significant (p < 0.05) associations of IHD with PM2.5 mass, nitrate, elemental carbon (EC), cop
185 o estimate the global and regional burden of IHD in 1990 and 2010.
186 h and aging led to a higher global burden of IHD in 2010.
187                         The global burden of IHD increased by 29 million disability-adjusted life-yea
188 % UI: 178 to 220 million) prevalent cases of IHD in 2019.
189                            Incident cases of IHD were identified through linkage with hospital record
190  concept of nonobstructive CAD as a cause of IHD and related adverse outcomes among women.
191 pants had a myocardial infarction or died of IHD.
192 rovide insight into the sexual dimorphism of IHD and may aid in the development of sex-specific thera
193 ,885 individuals aged 20 to 93 years free of IHD were followed from 1976 through 1978 until June 2011
194 lidation process led to an ensemble model of IHD mortality for 21 world regions.
195 nfatal IHD increased more than the number of IHD deaths since 1990, but >90% of IHD disability-adjust
196  of iTFAs could avert substantial numbers of IHD events and deaths in Australia and would likely be a
197 T cells prior to challenge with 10(4) PFU of IHD-J-Luc and treated with BCV postchallenge survived th
198 , and survived rechallenge with 10(5) PFU of IHD-J-Luc VACV without additional BCV treatment.
199 F or nonischemic HF based on the presence of IHD) was assessed through registry linkages.
200 cted mortality regardless of the presence of IHD, with adjusted hazard ratios (HRs) and 95% confidenc
201 ed outcomes, specifically in the presence of IHD.
202 F with regard to both a higher prevalence of IHD and a greater risk of new IHD events.
203 rth weight was associated with lower risk of IHD (odds ratio (OR) 0.96 per 100 grams, 95% confidence
204  but was associated with a 22% lower risk of IHD (RR: 0.78; 95% CI: 0.67, 0.92).
205                                  The risk of IHD and MI increased stepwise with increasing number of
206 both women and men, absolute 10-year risk of IHD and MI increased with increasing number of visible a
207 ole grains was associated with lower risk of IHD death.
208 %, -1.29%) was associated with lower risk of IHD death.
209 nt IHD was associated with increased risk of IHD events and all other outcomes in all EF categories e
210                         The adjusted risk of IHD events was similar for HFmrEF versus HFrEF and lower
211 es that explained the highest excess risk of IHD from genetically determined obesity were low-density
212 , 1.14)] and fiber intake with lower risk of IHD mortality [men: 0.94 (95% CI: 0.82, 1.08); women: 0.
213 asmata was associated with increased risk of IHD or MI after multifactorial adjustment for chronologi
214 ization suggest that ALT reduces the risk of IHD, probably through reducing triglyceride levels.
215 d remnant cholesterol with 7% excess risk of IHD.
216 ed between circulating magnesium and risk of IHD.
217  eggs was associated with ~20% lower risk of IHD.
218 nnot be explained by their increased risk of IHD.
219 0.2 mmol/L) and trends toward lower risks of IHD (RR: 0.83; 95% CI: 0.75, 1.05) and fatal IHD (RR: 0.
220                   Radiation-related risks of IHD decreased significantly with increasing time since f
221 tudy was to determine the long-term risks of IHD in women by pregnancy duration.
222  dose fractionation effect in dose trends of IHD was observed, with the highest estimate of ERR/Gy fo
223 g features of various anatomical variants of IHD using magnetic resonance cholangio-pancreatography (
224  genetic risk load has an additive effect on IHD risk.
225 ith more generalized inclusion or focused on IHD may be warranted.
226 t models were used to estimate the impact on IHD burden and health equity, as well as the cost-effect
227 ng evidence for an effect of birth weight on IHD and lipids.
228 is to estimate the effect of birth weight on IHD using the CARDIoGRAMplusC4D 1000 Genomes based GWAS
229 troke in patients with a prior MI (10.8%) or IHD (8.9%).
230 stry with respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, and all-cause death), an
231 d with cardiovascular diseases, particularly IHD and HF, which contribute significantly to all-cause
232 ions provide additional value for predicting IHD risk.
233 with ischemic heart disease (IHD), premature IHD, and severe hypercholesterolemia (low-density lipopr
234 H prevalence in subjects with IHD, premature IHD, and severe hypercholesterolemia compared with those
235  among 31,316 unique subjects with premature IHD (1,471 patients with FH) on the basis of 32 studies,
236 D, 20-fold higher among those with premature IHD, and 23-fold higher among those with severe hypercho
237                  After adjustment, prevalent IHD was associated with increased risk of IHD events and
238 nical follow-up and interventions to prevent IHD in women.
239 es not prove that a ban of iTFA will prevent IHD, rather, it provides the best quantitative estimates
240                                Age, previous IHD and diabetes, Killip class, creatinine, hemoglobin a
241 a control group of patients without previous IHD undergoing similar surgical procedures (n = 20,232).
242 fter intranasal infection with a recombinant IHD-J-Luc VACV expressing luciferase.
243 tranasal route with 10(5) PFU of recombinant IHD-J-Luc VACV expressing luciferase.
244 stralian food supply could result in reduced IHD mortality and morbidity while improving health equit
245 ies 2010 Study estimated global and regional IHD mortality from 1980 to 2010.
246 gly positively associated with self-reported IHD, systolic and diastolic blood pressure, low-density
247 ck of recognition is related to sex-specific IHD pathophysiology that differs from traditional models
248                         Patients with stable IHD enrolled in the REMIT (Responses of Mental Stress-In
249 between male and female patients with stable IHD.
250                   Globally, age-standardized IHD mortality has declined since the 1980s, and high-inc
251                        High age-standardized IHD mortality in Eastern Europe, Central Asia, and South
252                             Age-standardized IHD mortality increased in former Soviet Union countries
253 rly in high-income regions, age-standardized IHD mortality rates have declined significantly since 19
254                             Age-standardized IHD mortality rates per 100 000 people per year were muc
255 entral Asia had the highest age-standardized IHD mortality rates.
256                                          The IHD burden attributable to TFA was calculated by compari
257        Work disability leveled off among the IHD cases but not among those who had stroke.
258 t differences in disability days between the IHD and stroke cases and five years prior to the event,
259     This remained true when neutralizing the IHD-J strain, which lacks a functional version of the fo
260 sted life-years in 2010 were attributable to IHD deaths.
261             The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million
262 able for 1519 non cases, who were matched to IHD cases by sex and age.
263 servational studies, coffee was unrelated to IHD, and, as expected, childhood cognition.
264 sumption was inversely associated with total IHD (5 studies; 6514 events; RR per 4 weekly 100-g servi
265 ed States, Brazil, Kazakhstan, and Ukraine), IHD was the top cause of death, but mortality from IHD h
266 onfidence interval, 0.70-0.82, P<0.001) with IHD and 0.95 (95% confidence interval, 0.85-1.07; P=0.43
267 ociated with low-grade inflammation and with IHD, whereas elevated LDL cholesterol is associated caus
268 , ALT levels were negatively associated with IHD (odds ratio (OR) 0.92, 95% confidence interval (CI)
269           IDO1 was inversely associated with IHD (odds ratio (OR) 0.96 per standard deviation, 95% co
270 ted thyroid function was not associated with IHD (odds ratio (OR) per standard deviation for TSH 1.05
271        ILD was independently associated with IHD and HF, both of which were associated with mortality
272 al carbon (EC) soot was also associated with IHD mortality (HR = 1.03; 95% CI: 1.00, 1.06 per 0.26-mu
273  and their food sources were associated with IHD mortality in a Chinese population.
274  carbohydrate intake was not associated with IHD mortality risk [men: HR per 5% of energy, 0.97 (95%
275 d biomass combustion was not associated with IHD mortality.
276 nsumed was not substantially associated with IHD mortality.
277 te whether dietary SFAs were associated with IHD risk and whether associations depended on 1) the sub
278 ion and plasma magnesium are associated with IHD risk.
279     Asthma was independently associated with IHD, and multiple cardiovascular diseases contributed to
280                            Associations with IHD mortality varied by PM2.5 mass constituent and sourc
281  LDL cholesterol is associated causally with IHD without inflammation.
282 -up, 49,955 (2.3%) women were diagnosed with IHD.
283 to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors in the Guangzho
284 to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors.
285 t-line approach in consecutive patients with IHD (n=15).
286                    BM from 280 patients with IHD and LV dysfunction were analyzed for cell subsets by
287 roup study was conducted in 66 patients with IHD and LVH, comparing 600 mg/day allopurinol versus pla
288 proves endothelial function in patients with IHD and LVH.
289 hypertrophy (LVH) is common in patients with IHD including normotensive patients.
290                    Fifty-three patients with IHD, referred for a first VT ablation to our institution
291 tion in the first procedure in patients with IHD.
292 ge were also protected from rechallenge with IHD-J-Luc or WRvFire VACV without additional treatment.
293 sium excretion had a nonlinear relation with IHD risk (P-curvature = 0.01).
294 3% [1:31]) among 84,479 unique subjects with IHD (2,103 patients with FH) on the basis of 28 studies,
295  estimates of FH prevalence in subjects with IHD, premature IHD, and severe hypercholesterolemia comp
296 revalence is 10-fold higher among those with IHD, 20-fold higher among those with premature IHD, and
297                                   Those with IHD, particularly new IHD events, were also more likely
298 fidence interval, 0.85-1.07; P=0.430 without IHD.
299 .30 (1.22 to 1.39) in those with and without IHD, respectively.
300 cardiac death compared with patients without IHD.

 
Page Top